ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

NCT06838676 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Intrinsic Pontine Gliomas (DIPG)
Progressive DIPG
Refractory DIPG
Recurrent DIPG
H3K27-altered High Grade Glioma

Interventions

DRUG: ACT001

Sponsor

Nationwide Children's Hospital

Collaborators

[object Object]